CtDNA based molecular residual disease outcompetes carcinoembryonic antigen in predicting postoperative recurrence of non-small cell lung cancer.

"Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-507/coif). The authors have no conflicts of interest to declare."

"Funding: This work was supported by the Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine ( Grant No. 2017B030314120 to W.Z.Z.), the National Natural Science Foundation of China Major Joint Project on Key scientific issues of Lung Cancer ( Grant No. 82241235 to W.Z.Z.), the Guangdong Basic and Applied Basic Research Foundation ( Grant No.2019B1515130002 to W.Z.Z.) and the High-level Hospital Construction Project ( Grant No. DFJH201801 ). The funding sources had no role in the preparation of this manuscript."